Composite films of poly(vinyl alcohol)–chitosan–bacterial cellulose for drug controlled release

Păvăloiu, Ramona-Daniela; Stoica-Guzun, Anicuţa; Stroescu, Marta; Jinga, Sorin‐Ion; Dobre, Tănase

doi:10.1016/j.ijbiomac.2014.04.040

Cited by 98 publications

(38 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was found that the release rate of thymol was slowed down for multilayer film compared with monolayer film and it reduced as the thickness of exterior layers of multilayer film increased. The similar results were also reported that the multilayer films were used for the drug controlled release (Müllers et al., ; Pavaloiu et al., ). The current studies were mainly focused on verifying that the release of active agents can be delayed by the multilayer structure.…”

Section: Introductionsupporting

confidence: 81%

“…Developing active packaging films with control release property has been the goal of many recent researches. Several technologies were employed to control the release rate of active agents, such as blend (Castro, Dopico, Pernas, & Manuel, ; Han, Lu, & Ge, ; Lacoste, Schaich, Zumbrunnen, & Yam, ; Wattananawinrat, Threepopnatkul, & Kulsetthanchalee, ), microcapsule (Liu et al., ; Wen et al., ), porous material used as adsorption carrier (Gargiulo et al., ; Park, Hwang, Yoon, Lee, & Lee, ; Sun, Lu, Qiu, & Tang, ), and multilayer films (Guiga et al., ; Mastromatteo, Barbuzzi, Conte, & Nobile, ; Müllers, Wahl, & Pinto, ; Pasqual, Bermúdez, Aucejo, Catalá, & Gavara, ; Pavaloiu, Stoica‐guzun, Stroescu, Jinga, & Dobre, ). The controlled release system of multilayer films originated from the technology of lay by lay in the pharmaceutical field, which was introduced into the development of controlled release packaging later (Han, ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Development of New Multilayer Active Packaging Films with Controlled Release Property Based on Polypropylene/Poly(Vinyl Alcohol)/Polypropylene Incorporated with Tea Polyphenols

Chen

Yang

et al. 2019

Journal of Food Science

View full text Add to dashboard Cite

The polypropylene/poly(vinyl alcohol)/polypropylene (PP/PVA/PP) multilayer active films with controlled release property were developed, of which the intermediate PVA layer was incorporated with 4% (w/w) tea polyphenols (TP) and the microporous PP films with different pore size were used as the internal controlled release layer. The SEM results showed that each layer of these films was agglutinated tightly. With increasing pore size from 171.05 to 684.03 µm, there were little effect on the films’ color and opacity, the tensile strength (TS) and elongation at break (EAB) decreased slightly, the gas barrier (O2 and water vapor) property of the film reduced faintly, the time of achieving the release equilibrium in 50% ethanol decreased from 75 hours to 30 hours. The diffusion coefficient for the films increased with the increase of pore size, from 2.06 × 10−11 cm2/s to 8.06 × 10−11 cm2/s, suggesting that the release rate of TP increased as the pore size increased. The results were indicated that its release rate could be controlled by adjusting the size of pore. The films also exhibited different antioxidant activities due to their different release profiles of TP. It showed promise for developing the controlled release active packaging film based on this concept. Practical Application Controlled release packaging is propitious to extension of food shelf life. The microporous polypropylene films with different pore size used as the internal layer of polypropylene/poly(vinyl alcohol)/polypropylene (PP/PVA/PP) multilayer active films was proved that the release rate of tea polyphenols in the intermediate PVA layer released from the films into the food simulant can be controlled by adjusting the size of pore in this study. It showed a good prospect for using microporous or perforation‐mediated film as the internal layer of multilayer film to develop the controlled release active packaging film for food packaging.

show abstract

Section: Introductionsupporting

confidence: 81%

Section: Introductionmentioning

confidence: 99%

Development of New Multilayer Active Packaging Films with Controlled Release Property Based on Polypropylene/Poly(Vinyl Alcohol)/Polypropylene Incorporated with Tea Polyphenols

Chen

Yang

et al. 2019

Journal of Food Science

View full text Add to dashboard Cite

show abstract

“…As the content of PLGA was increased, the particle size of NPs was also increased from F1 (PLGA 5 mg) 124.7 ± 1.15 nm to F3 (PLGA 10 mg) 140.4 ± 1.34 nm. As the concentration of PLGA increases, the viscosity of the nanosuspension increases proportionally and efficiency of stirring decreases; thereby these phenomena lead to an increase in the size of the nanoparticles [17]. Also, particle size analysis showed a narrow range of variability in dispersion (PDI, 0.089 ± 0.02 -0.108 ± 0.03).…”

Section: Resultsmentioning

confidence: 99%

Evaluation of AML-VAL Nanoparticles as Combined Therapy in Cardiovascular Disease

Sha’at¹,

Pavaloiu²,

Salceanu³

et al. 2018

Mat.Plast.

View full text Add to dashboard Cite

The main aim of this study was to investigate a mixture of two poorly water-soluble active pharmaceutical ingredients (APIs): an angiotensin II receptor antagonist (valsartan) and a calcium channel blocker (amlodipine besylate), chosen in a fixed-dose, in order to obtain new polymeric nanoparticles (NPs) for cardiovascular diseases treatment. NPs were prepared via nanoprecipitation method using poly (D,L-lactide-co-glycolide) (PLGA) as matrix and Pluronic F127 as stabilizer. Three formulations were investigated with different ratios of AML:VAL:PLGA (1:16:5, 1:16:7.5 and 1:16:10). Particle size, polydispersity index and zeta-potential analyses were performed to characterize and optimize the formulation. The in vitro drug release study was determined by using a dialysis membrane method under sink conditions. All NPs loaded with both APIs showed nano-size, negative potential, a high homogeneity and a slow drugs release in physiological environment.

show abstract

“…In the cardiovascular treatment, super generics can improve solubility in aqueous media, for APIs, like: valsartan, irbesartan, nimodipine, carvediol, amlodipine besylate, etc. ; several methods have been developed to dispose this disadvantage, such as the use of surfactants, lipids, permeation promoters, micronization, use of salts, cyclodextrines, nanoparticles and solid dispersions [3,4]. In contrast to studies that have very good results for a single API and its matrix, this work is geared toward the study of nano-systems that contain two APIs encapsulated simultaneously in a biodegradable polymer.…”

mentioning

confidence: 99%

Formulation of Polymeric Multicomponent Systems Containing Cardiovascular APIs

Sha’at¹,

Pavaloiu²,

Salceanu³

et al. 2018

Mat.Plast.

View full text Add to dashboard Cite

The main aim of this study was to prepare and characterize polymeric nanoparticles containing two cardiovascular active pharmaceutical ingredients: valsartan (VAL) and amlodipine besylate (AML). Six formulations were evaluated with different ratios of AML:VAL:PLGA (1:16:17, 1:16:34, and 1:16:51) and different stirring speed (1200 and 2400 rpm). Encapsulation efficiency (EE, %) and particle size analyses were performed to characterize and optimize the formulation. All loaded nanoparticles showed a high EE (%), nano-size, negative x-potential and a high homogeneity.

show abstract

Composite films of poly(vinyl alcohol)–chitosan–bacterial cellulose for drug controlled release

Cited by 98 publications

References 39 publications

Development of New Multilayer Active Packaging Films with Controlled Release Property Based on Polypropylene/Poly(Vinyl Alcohol)/Polypropylene Incorporated with Tea Polyphenols

Development of New Multilayer Active Packaging Films with Controlled Release Property Based on Polypropylene/Poly(Vinyl Alcohol)/Polypropylene Incorporated with Tea Polyphenols

Evaluation of AML-VAL Nanoparticles as Combined Therapy in Cardiovascular Disease

Formulation of Polymeric Multicomponent Systems Containing Cardiovascular APIs

Contact Info

Product

Resources

About